Life Sciences Opportunities in India & China: From Innovation to Commercialization
September 30, 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
December 17, 2025
Foley Viewpoints
SEC and FINRA Increase Oversight of Cross-Border Small-Cap Offerings
Executive Summary In late 2025, the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA)…
December 17, 2025
Foley Viewpoints
Amended Regulation S-P: Here to Stay and Being Examined in 2026
Last month, the U.S. Securities and Exchange Commission (SEC) Division of Examinations released its Fiscal Year 2026 “Examination…
December 17, 2025
Foley Viewpoints
It’s a Wonderful Hypo: What if the Bailey Bros. Building & Loan Was a SEC Registered Investment Adviser?
In the 1946 film “It’s a Wonderful Life,” George Bailey is despondent after a series of mishaps — including his family member and…